Robert C. Doebele, MD, PhD, discusses a retrospective trial comparing the efficacy of entrectinib with crizotinib in the treatment of patients with ROS1-positive non–small cell lung cancer.
Original Article: Entrectinib Shows Real-World PFS Benefit in ROS1+ NSCLC